Multiple Sclerosis (MS) Models

Advance your multiple sclerosis agents through the drug development process with our preclinical inflammation platform.

Key Benefits:

• Utilize well-validated models, including the MOG-EAE model which closely represents the human condition.
• Determine efficacy and response to treatment
• Select Qualified lead agents

Gain a comprehensive profile of genes associated with tumor immunity by measuring 1080 mouse transcripts from a single sample.

Deeply profile the immunogenomics of murine tumorimmune interactions to select preclinical models with diverse mechanisms that capture many of the key characteristic clinical and pathologic features of MS including:

• Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (MOG-EAE) model
• Proteolipid protein-induced experimental autoimmune encephalomyelitis (PLP-EAE) relapsing-remitting model coming soon

MOG-EAE model

Mice are immunized with MOG35-55 myelin-associated peptide in complete Freunds adjuvant, then treated with pertussis toxin to promote increased transport of leukocytes across the bloodbrain barrier.

• Disease onset occurs after day 10

Major endpoints for assessment:

• Body weight measurements
• Disease Paralysis Scoring (daily after day 10)
• Cytokine levels
• FACS analysis of immune cell populations
• Perfusion of the brain and spinal cord for histopathology assessment